Cell-produced α-synuclein oligomers are targeted to, and impair, the 26S proteasome

Neurobiology of Aging

Volumn 31, Issue 6, 2010, Pages 953-968

  Emmanouilidou, Evangelia ^a   Stefanis, Leonidas ^a,b   Vekrellis, Kostas ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Synuclein; 26S proteasome; Aggregation; Neurodegeneration; Oligomers; Parkinson's Disease

Indexed keywords

26S PROTEASOME; ALPHA SYNUCLEIN; OLIGOMER; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME ACTIVITY; ENZYME SUBSTRATE; GEL FILTRATION; MOUSE; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ALANINE; ALPHA-SYNUCLEIN; AMMONIUM CHLORIDE; ANIMALS; BENZOQUINONES; CEREBRAL CORTEX; CHROMATOGRAPHY, GEL; COLORING AGENTS; CONGO RED; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOPRECIPITATION; LACTAMS, MACROCYCLIC; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PC12 CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN FOLDING; RATS; TRANSFECTION; TYROSINE;

EID: 77951976610     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.07.008     Document Type: Article

References (70)

1. Akaishi T., Yokosawa H., Sawada H. Regulatory subunit complex dissociated from 26S proteasome, isolation and characterization. Biochim. Biophys. Acta 1995, 1245:331-338.
2. Ancolio K., Alves da Costa C., Ueda K., Checler F. Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci. Lett. 2000, 285:79-82.
3. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., Bonini N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002, 295:865-868.
4. Auluck P.K., Meulener M.C., Bonini N.M. Mechanisms of suppression of {alpha}-synuclein neurotoxicity by geldanamycin in Drosophila. J. Biol. Chem. 2005, 280:2873-2878.
5. Baba M., Nakajo S., Tu P.-H., Tomita T., Kakaya K., Lee V.M., Trojanowski J.-Q., Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 1998, 152:879-884.
6. Benaroudj N., Zwickl P., Seemüller E., Baumeister W., Goldberg A.L. ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation. Mol. Cell 2003, 11:69-78.
7. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
8. Bennett M.C., Bishop J.F., Leng Y., Chock P.B., Chase T.N., Mouradian M.M. Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 1999, 274:33855-33858.
9. Carter D.B., Chou K.C. A model for structure-dependent binding of Congo red to Alzheimer beta-amyloid fibrils. Neurobiol. Aging 1998, 19:37-40.
10. Chan H.Y., Warrick J.M., Gray-Board G.L., Paulson H.L., Bonini N.M. Mechanisms of chaperone suppression of polyglutamine disease, selectivity, synergy and modulation of protein solubility in Drosophila. Hum. Mol. Genet. 2000, 9:2811-2820.
11. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., Destée A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
12. 5 subunit increases the amount of assembled proteasome and confers ameliorated response to oxidative stress and higher survival rates. J. Biol. Chem. 2005, 280:11840-11850.
13. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease, implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:571-576.
14. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001, 294:1346-1349.
15. Cuervo A.-M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant a-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
16. Cummings C.J., Mancini M.A., Antalffy B., DeFranco D.B., Orr H.T., Zoghbi H.Y. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 1998, 19:148-154.
17. Dickson D.-W., Liu W., Hardy J., Farrer M., Mehta N., Uitti R., Mark M., Zimmerman T., Golbe L., Sage J., Sima A., D'Amato C., Albin R., Gilman S., Yen S.H. Widespread alterations of alpha-synuclein in multiple system atrophy. Am. J. Pathol. 1999, 155:1241-2125.
18. Dixon C., Mathias N., Zweig R.-M., Davis D.-A., Gross D.-S. Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. Genetics 2005, 170:47-59.
19. De Los Rios P., Ben-Zvi A., Slutsky O., Azem A., Goloubinoff P. Hsp70 chaperones accelerate protein translocation and the unfolding of stable protein aggregates by entropic pulling. PNAS 2006, 103:6166-6171.
20. Evans C.G., Wisen S., Gestwicki J.E. Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J. Biol. Chem. 2006, 281:33182-33191.
21. Farrer M., Kachergus J., Forno L., Lincoln S., Wang D.S., Hulihan M., Maraganore D., Gwinn-Hardy K., Wszolek Z., Dickson D., Langston J.W. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 2004, 55:174-179.
22. Ghee M., Fournier A., Mallet J. Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. J. Neurochem. 2000, 75:2221-2224.
23. Ghee M., Melki R., Mishot N., Mallet J. PA700, the regulatory complex of the 26S proteasome, interferes with a-synuclein assembly. FEBS J. 2005, 272:4023-4033.
24. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34:521-533.
25. Golberg A.L. Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426:895-899.
26. Gosavi N., Lee H.-J., Lee J.-S., Patel S., Lee S.-J. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 2002, 277:48984-48992.
27. Heiser V., Scherzinger E., Boeddrich A., Nordhoff E., Lurz R., Schugardt N., Lehrach H., Wanker E.-E. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules, implications for Huntington's disease therapy. Proc. Natl. Acad. Sci. U.S.A. 2000, 92:6739-6744.
28. Hendil K.-B., Khan S., Tanaka K. Simultaneous binding of PA28 and PA700 activators to 20S proteasomes. Biochem. J. 1998, 332:749-754.
29. Hendil K.-B., Hartmann-Petersen R., Tanaka K. 26S proteasomes function as stable entities. J. Mol. Biol. 2002, 315:627-636.
30. Hoffman L., Rechsteiner M. Activation of the multicatalytic protease. J. Biol. Chem. 1994, 269:16890-16895.
31. Hoglinger G.U., Carrard G., Michel P.P., Medja F., Lombes A., Ruberg M., Friguet B., Hirsch E.C. Dysfunction of mitochondrial complex I and the proteasome, interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem. 2003, 86:12097-21307.
32. Holmberg C.I., Staniszewski K.E., Mensah K.N., Matouschek A., Morimoto R.I. Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J. 2004, 23:4307-4318.
33. Jabado O., Wang Q., Rideout H.J., Yeasmin M., Guo K.X., Vekrellis K., Papantonis S., Angelastro J.M., Troy C.M., Stefanis L. RAIDD aggregation facilitates apoptotic death of PC12 cells and sympathetic neurons. Cell Death Diff. 2004, 11:618-630.
34. Jariel-Encontre I., Pariat M., Martin F., Carillo S., Salvat C., Piechaczyk M. Ubiquitinylation is not an absolute requirement for degradation of c-Jun protein by the 26 S proteasome. J. Biol. Chem. 1995, 270:11623-11627.
35. Kahle P.-J., Neumann N., Ozmen L., Muller V., Odoy S., Okamoto N., Jacob sen H., Iwatsubo T., Trojanowski J.-Q., Takahashi H., Wakabayashi K., Bogdanovic N., Riederer P., Kretzschmar H.A., Haass C. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am. J. Pathol. 2001, 159:2215-2225.
36. Kayed R., Head E., Thompson J.-L., McIntire T.-M., Milton S.-C., Cotman C.-W., Glabe C.-G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
37. Klucken J., Shin Y., Masliah E., Hyman B.T., McLean P.J. Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem. 2004, 279:25497-254502.
38. Kristiansen M., Deriziotis P., Dimcheff D.E., Jackson G.S., Ovaa H., Naumann H., Clarke A.R., van Leeuwen F.W., Menendez-Benito V., Dantuma N.P., Portis J.L., Collinge J., Tabrizi S.J. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol. Cell. 2007, 26:175-188.
39. Lang-Rollin I., Rideout H., Stefanis L. Ubiquitinated inclusions and neuronal cell death. Histol. Histopathol. 2003, 18:509-517.
40. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., Lansbury P.T. a-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 2002, 322:1089-1102.
41. Lee H.J., Khoshaghideh F., Patel S., Lee S.J. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J. Neurosci. 2004, 24:1888-1896.
42. Lindersson E., Beedholm R., Hojrup P., Moos T., Gai W., Hendil K.B., Jensen P.H. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J. Biol. Chem. 2004, 279:12924-12934.
43. Liu Y., Fallon L., Lashuel H.-A., Liu Z., Lansbury P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002, 111:209-218.
44. Martin-Clemente B., Alvarez-Castelao B., Mayo I., Sierra A.B., Diaz V., Milan M., Farinas I., Gomez-Isla T., Ferrer I., Castano J.G. α-Synuclein expresion levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines. J. Biol. Chem. 2004, 279:52984-52990.
45. McLean P.J., Klucken J., Shin Y., Hyman B.T. Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem. Biophys. Res. Commun. 2004, 321:665-669.
46. Outeiro T.F., Putcha P., Tetzlaff J.E., Spoelgen R., Koker M., Carvalho F., Hyman B.T., McLean P.J. Formation of toxic oligomeric α-synuclein species in living cells. PLOS One 2008, 3:e1867.
47. Paxinou E., Chen Q., Weisse M., Giasson B.-I., Norris E.-H., Rueter S.-M., Trojanowski J.-Q., Lee V.M., Ischiropoulos H. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 2001, 21:8053-8061.
48. Petrucelli L., O'Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., Choi P., Wolozin B., Farrer M., Hardy J., Cookson M.R. Parkin protects against the toxicity associated with mutant alpha-synuclein, proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002, 36:1007-1019.
49. Pickart C.M., Cohen R.E. Proteasomes and their kin, proteases in the machine age. Nat. Rev. Mol. Cell Biol. 2004, 5:177-187.
50. Rideout H.J., Larsen K.E., Sulzer D., Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/α-synuclein immunoreactive inclusions in PC12 cells. J. Neurochem. 2001, 78:899-908.
51. Rideout H.J., Stefanis L. Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol. Cell Neurosci. 2002, 21:223-238.
52. Rivett J.A., Bose S., Pemberton A.J., Brooks P., Onion D., Shirley D., Stratford F.L.L., Forti K. Assays of proteasome activity in relation to aging. Exp. Gerontol. 2002, 37:1217-1222.
53. Rodgers K.J., Dean R.T. Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates. Int. J. Biochem. Cell Biol. 2003, 35:716-727.
54. Sanchez I., Mahlke C., Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003, 421:373-379.
55. Sawada H., Kohno R., Kihara T., Izumi Y., Sakka N., Ibi M., Nakanishi M., Nakamizo T., Yamakawa K., Shibasaki H., Yamamoto N., Akaike A., Inden M., Kitamura Y., Taniguchi T., Shimohama S. Proteasome mediates dopaminergic neuronal degeneration and its inhibition causes a-synuclein inclusions. J. Biol. Chem. 2004, 279:10710-10719.
56. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
57. Smith D.M., Chang S.C., Park S., Finley D., Cheng Y., Goldberg A.L. Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's a ring opens the gate for substrate entry. Mol. Cell 2007, 27:731-744.
58. Smith W.W., Jiang H., Pei Z., Tanaka Y., Morita H., Sawa A., Dawson V.L., Dawson T.M., Ross C.A. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutantalpha-synuclein-inducedtoxicity. Hum. Mol. Genet. 2005, 14:3801-3811.
59. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A., Wolozin B. Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 2003, 278:11753-11759.
60. Stefanis L., Larsen K.E., Rideout H.J., Sulzer D., Greene L.A. Expression of A53T mutant but not wild-type a-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 2001, 21:9549-9560.
61. Stefanis L., Kholodilov N., Rideout H.J., Burke R.E., Greene L.A. Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells. J. Neurochem. 2001, 76:1165-1176.
62. Tanaka E., Sawada M.T., Morinaga C., Yokosawa H., Sawada H. Isolation and characterization of a novel 530-kDa protein complex (PC530. capable of associating with the 20S proteasome from Starfish oocytes. Arch. Biochem. Biophys. 2000, 374:181-188.
63. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawada A., Dawson V.L., Dawson T.M., Ross C.A. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 2001, 10:919-926.
64. Tofaris G.K., Layfield R., Spillantini M.G. Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 2001, 509:22-26.
65. Treier M., Staszewski L.M., Bohmann D. Ubiquitin-dependent c-jun degradation in vivo is mediated by the delta domain. Cell 1994, 78:787-798.
66. Tseng, B.P., Green, K.N., Chan, J.L., Blurton-Jones, M., Laferla, F.M., 2007. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol. Aging, 2007, doi:10.1016/j.neurobiolaging.2007.04.014.
67. Vekrellis K., Rideout H.J., Stefanis L. Neurobiology of a-synuclein. Mol. Neurobiol. 2004, 30:1-21.
68. Vekrellis K., Stefanis L. Ubiquitin and the proteasome in neurodegeneration 2005, Kluwer Academic/Plenum, NY. J.N. Keller, L. Stefanis (Eds.).
69. Volles M.J., Lansbury P.T. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003, 42:7871-7878.
70. Webb J.L., Ravikumar B., Atkins J., Skepper J.N., Rubinstein D.C. Alpha-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 2003, 278:25009-32501.